Glaukos stock gains momentum as GKOS approaches 52-week high

Glaukos Corporation stock (ISIN US3773221029) has delivered a year-to-date performance of 44.78 percent as of September 17, 2026, underscoring strong momentum in the ophthalmic device and drug segment for retail investors watching the mid-cap healthcare space.Seeking Alpha highlights Glaukos as one of the US healthcare names with an A momentum grade.

Glaukos fundamentals and market position

Glaukos Corporation, based in California and listed on the New York Stock Exchange under the ticker GKOS, focuses on ophthalmic medical devices and therapies, particularly for glaucoma and corneal disorders. As a component holding in the iShares Russell 2000 ETF, GKOS represents 0.32 percent of the portfolio weight, with 1.5 million shares held and a market value of USD 257.2 million as of the close on September 16, 2026, which signals meaningful representation in the small-cap benchmark.Charles Schwab shows GKOS among the healthcare names in IWM.

According to data compiled by Macrotrends, Glaukos carries a market capitalization of USD 5.495 billion, placing it firmly in the US mid-cap healthcare cohort as of mid-September 2026.

Recent performance and momentum signal

In the healthcare momentum overview published on September 17, 2026, Seeking Alpha assigns Glaukos an A momentum grade and reports a year-to-date performance of 44.78 percent. This places GKOS significantly ahead of broad US equity benchmarks in 2026 and flags the stock as one of the more dynamic healthcare names this year.

The strong YTD gain of 44.78 percent as of September 17, 2026 can be viewed against the Russell 2000 component data, where the ETF’s total market value exposure to Glaukos stands at USD 257.2 million for 1.5 million shares, indicating that index investors are also participating in the run-up.Charles Schwab provides the holdings breakdown that supports this view.

Stock level and investor takeaway

Per a recent multi-company healthcare data table that cites Glaukos at USD 161.20 with a daily move of minus 1.39 percent in USD, GKOS trades close to its recent 52-week high range while retaining a robust year-to-date performance as of mid-September 2026.Yahoo Finance lists Glaukos alongside other healthcare names with live price snapshots. For investors, the combination of a USD 5.495 billion market capitalization, a 44.78 percent YTD gain, and an A momentum grade paints the picture of a mid-cap healthcare stock that has already rerated significantly in 2026 but still commands attention in ophthalmic innovation.

More news and analyses on Glaukos Corporation stock